Filter by

Responsible body
Patient safety

Results (3620)


Casgevy gene editing therapy picture showing DNA on blue background

EMA has recommended approval of the first medicine using CRISPR/Cas9, a novel gene-editing technology. Casgevy (exagamglogene autotemcel) is indicated for the treatment of transfusion‑dependent beta thalassemia and severe sickle cell disease in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a...

NewsHumanMedicines